Hyloris Pharmaceuticals Statistics

Total Valuation

Hyloris Pharmaceuticals has a market cap or net worth of EUR 145.04 million. The enterprise value is 118.97 million.

Market Cap	145.04M
Enterprise Value	118.97M

Important Dates

The next estimated earnings date is Thursday, March 20, 2025.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Hyloris Pharmaceuticals has 28.00 million shares outstanding. The number of shares has increased by 1.44% in one year.

Current Share Class	n/a
Shares Outstanding	28.00M
Shares Change (YoY)	+1.44%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	56.83%
Owned by Institutions (%)	0.27%
Float	12.09M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	21.24
PB Ratio	4.34
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-8.98
EV / Sales	17.14
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.64

Financial Position

The company has a current ratio of 3.71, with a Debt / Equity ratio of 0.05.

Current Ratio	3.71
Quick Ratio	3.66
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	-0.15
Interest Coverage	-141.88

Financial Efficiency

Return on equity (ROE) is -31.76% and return on invested capital (ROIC) is -19.79%.

Return on Equity (ROE)	-31.76%
Return on Assets (ROA)	-16.75%
Return on Capital (ROIC)	-19.79%
Revenue Per Employee	169,293
Profits Per Employee	-323,000
Employee Count	41
Asset Turnover	0.14
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -59.21% in the last 52 weeks. The beta is 0.45, so Hyloris Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.45
52-Week Price Change	-59.21%
50-Day Moving Average	5.55
200-Day Moving Average	9.63
Relative Strength Index (RSI)	56.12
Average Volume (20 Days)	19,369

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Hyloris Pharmaceuticals had revenue of EUR 6.94 million and -13.24 million in losses. Loss per share was -0.47.

Revenue	6.94M
Gross Profit	6.79M
Operating Income	-13.76M
Pretax Income	-13.24M
Net Income	-13.24M
EBITDA	-13.53M
EBIT	-13.76M
Loss Per Share	-0.47

Full Income Statement

Balance Sheet

The company has 27.96 million in cash and 1.89 million in debt, giving a net cash position of 26.07 million or 0.93 per share.

Cash & Cash Equivalents	27.96M
Total Debt	1.89M
Net Cash	26.07M
Net Cash Per Share	0.93
Equity (Book Value)	34.66M
Book Value Per Share	1.19
Working Capital	23.94M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -12.02 million and capital expenditures -320,000, giving a free cash flow of -12.34 million.

Operating Cash Flow	-12.02M
Capital Expenditures	-320,000
Free Cash Flow	-12.34M
FCF Per Share	-0.44

Full Cash Flow Statement

Margins

Gross margin is 97.77%, with operating and profit margins of -198.27% and -190.79%.

Gross Margin	97.77%
Operating Margin	-198.27%
Pretax Margin	-190.79%
Profit Margin	-190.79%
EBITDA Margin	-194.86%
EBIT Margin	-198.27%
FCF Margin	-177.71%

Dividends & Yields

Hyloris Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.44%
Shareholder Yield	-1.44%
Earnings Yield	-8.99%
FCF Yield	-8.50%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Hyloris Pharmaceuticals has an Altman Z-Score of 15.92.

Altman Z-Score	15.92
Piotroski F-Score	n/a